Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

被引：0

作者：

Delicou, Sophia ^{[1
]}

El Rassi, Fuad ^{[2
]}

Andemariam, Biree ^{[3
]}

Abboud, Miguel R. ^{[4
]}

Kanter, Julie ^{[5
]}

Telen, Marilyn J. ^{[6
]}

Githanga, Jessie ^{[7
]}

Inati, Adlette ^{[8
]}

Idris, Ibrahim ^{[9
]}

Navani, Sunil ^{[10
]}

Wu, Eric ^{[11
]}

Eisenberger, Andrew ^{[12
]}

机构：

[1] Hippokrateio Gen Hosp, Athens, Greece

[2] Emory Univ, Sch Med, Atlanta, GA USA

[3] Univ Connecticut Hlth, Farmington, CT USA

[4] Amer Univ Beirut, Beirut, Lebanon

[5] Univ Alabama Birmingham, Birmingham, AL USA

[6] Duke Univ, Med Ctr, Durham, NC USA

[7] Univ Nairobi, Nairobi, Kenya

[8] Lebanese Amer Univ, Byblos & NINI Hosp, Gilbert & Rose Marie Chagoury Sch Med, Tripoli, Lebanon

[9] Bayero Univ, Aminu Kano Teaching Hosp, Kano, Nigeria

[10] Novo Nordisk Ltd, Oxford, England

[11] Novo Nordisk Co, Lexington, MA USA

[12] Columbia Univ, New York, NY USA

来源：

关键词：

D O I：

10.1182/blood-2024-204962

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：179 / 180

页数：2